Some of the data that’s coming out from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 will be helpful in figuring out where combination approaches can be utilized when it comes to treating patients with prostate cancer. Not to mention, that there are also PARP inhibitors and others that can be worked together with radiopharmaceutical therapy to prevent the cancer cells from regenerating after the damage occurred by radiopharmaceutical therapies. To learn more, join Dr. Munir Ghesani, Chief Medical Officer and Medical Director at United Theranostics in Princeton.
